New drug IGT-303 tested for kidney disease safety

NCT ID NCT07231679

First seen Nov 17, 2025 · Last updated May 23, 2026 · Updated 19 times

Summary

This early-stage study tests whether IGT-303 is safe for people with chronic kidney disease. About 94 healthy volunteers and kidney disease patients will receive either the drug or a placebo. Researchers will monitor side effects and how the drug moves through the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Momentum Clinical Research

    RECRUITING

    Waikanae Beach, Kapiti Coast, 5036, New Zealand

  • Nucleus Network

    RECRUITING

    Herston, Brisbane, 4006, Australia

  • Pacific Clinical Research Network

    RECRUITING

    Takapuna, Auckland, 0622, New Zealand

  • University of Sunshine Coast-Morayfield

    RECRUITING

    Morayfield, Queensland, 4506, Australia

  • University of the Sunshine Coast Clinical Trials-Southbank

    RECRUITING

    Morayfield, Queensland, 4506, Australia

Conditions

Explore the condition pages connected to this study.